查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1797939

全球生育治疗服务市场：2032 年预测 - 按治疗类型、不孕症原因、最终用户和地区进行分析

Fertility Services Market Forecasts to 2032 - Global Analysis By Treatment Type (Assisted Reproductive Technology and Artificial Insemination ), Infertility Cause, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球生育服务市场预计在 2025 年达到 494 亿美元，到 2032 年将达到 858 亿美元，预测期内的复合年增长率为 8.2%。

生育服务涵盖一系列旨在帮助个人或夫妇受孕的治疗、诊断程序和支持性解决方案。这些服务包括辅助生殖技术 (ART)，例如体外受精 (IVF)、子宫内人工授精 (IUI)、生育力保存、荷尔蒙疗法和诊断检测。市场成长的驱动力包括：不孕症上升、生育延迟以及生殖保健意识的增强，而技术进步和专业生育诊所及照护网路的普及也推动了这个市场的成长。

不孕不育率上升

根据世界卫生组织 (WHO) 2023 年的报告，全球约六分之一的成年人面临不孕症的困扰，约占成年人口的 17.5%。肥胖、慢性压力和过量饮酒等不良生活习惯，以及卵巢症候群 (PCOS) 等常见疾病，是导致不孕率下降的重要原因。此外，都市区推迟受孕的趋势日益明显，老年女性卵子品质下降，也推动了对先进不孕症治疗的需求，为全球服务供应商创造了巨大的市场机会。

不孕不育治疗费用高昂

不孕症治疗，尤其是体外受精（IVF）和先进的辅助生殖技术，需要大量的资金投入，通常超过一个治疗週期。许多患者需要多次尝试才能成功受孕，这进一步增加了整体费用负担。此外，由于各地区不孕症治疗的保险保障范围有限，夫妻不得不自掏腰包。这些经济限制尤其影响中等收入者，他们的收入通常过高，不符合援助计画的资格，但仍缺乏经济能力来轻鬆负担全面的不孕症治疗。

在新兴市场扩张

生育诊所和专科治疗中心在亚太地区、拉丁美洲和新兴国家正在迅速扩张。政府推出的生殖保健倡议，加上人们对生育治疗方案日益增长的认识，正在创造有利的市场条件。此外，新兴市场的医疗旅游业蓬勃发展，为国际患者提供了经济实惠的生育治疗方案，使这些地区成为全球生育中心。

文化和宗教的反对

传统观念对不孕症治疗（尤其是涉及捐赠配子和代孕的治疗）在某些群体中引发了抵制。反对人工生殖介入的宗教教义限制了某些群体对不孕症的市场接受度和利用率。此外，围绕不孕症问题的社会污名化阻碍了许多夫妇寻求必要的治疗，从而降低了整体市场需求。此外，各国法律体制和伦理考量的差异可能会使服务提供者的业务复杂化，并限制其扩大策略。

COVID-19的影响：

新冠疫情最初扰乱了全球的生育服务，许多诊所在封锁期间暂停了非必要的治疗。然而，随着各国政府加强通讯协定，帮助生育中心重新开放，市场展现惊人的韧性。许多夫妇利用这段时间规划治疗，导致服务恢復后需求增加。此外，疫情带来的压力以及封锁期间受孕延迟导致生育服务的使用率上升，促进了市场在疫情后的復苏和加速成长。

预计女性不孕症领域将成为预测期内最大的领域

由于各种生理和生活方式因素影响女性生殖功能，预计女性不孕症领域将在预测期内占据最大的市场占有率。卵巢症候群 (PCOS)、子宫内膜结核和卵巢早衰等疾病的盛行率不断上升，显着增加了女性不孕症。此外，都市区职业妇女生育年龄延迟的趋势日益明显，导致生育能力老龄化下降，对专科治疗的需求也日益增加。先进的女性不孕症评估诊断技术，加上卵子冷冻和荷尔蒙疗法等创新治疗方案，进一步巩固了该领域的主导地位。

预计在预测期内，不孕症治疗诊所部门的复合年增长率最高。

生育诊所细分市场预计将在预测期内实现最高成长率，这得益于其专业化和全面的治疗服务。这些专门的机构提供最先进的设备、专业知识以及专为生殖保健设计的个人化治疗通讯协定。该行业受益于全球独立生育中心的日益增多，尤其是在采用人工智慧辅助胚胎选择和延时成像等先进技术的已开发地区。此外，生育诊所能够在同一地点提供标准和复杂的治疗，加上高成功率以及与精子银行和卵子库的合作，预计将推动其持续成长。

比最大的地区

预计北美将在预测期内占据最大的市场占有率。该地区的主导地位归功于其先进的医疗基础设施、对不孕症治疗的高度认知以及覆盖多个地区的全面保险覆盖。尤其是美国，凭藉其领先的不孕症诊所、技术创新以及辅助生殖技术的广泛接受，正在推动该地区的成长。此外，北美夫妇推迟生育的趋势日益明显、不孕症盛行率的上升以及支持性的法律规范，都是巩固该地区市场领导地位的因素。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这得益于快速的经济发展和医疗基础设施的改善。包括中国、印度和东南亚在内的许多国家，生育诊所的开设数量和治疗可近性正在显着增加。可支配收入的增加、人们对生育治疗方案的认知度不断提高以及对现代生殖技术的日益接受，都促成了这一显着的成长轨迹。此外，政府对生殖保健的支持倡议，加上该地区庞大的人口和不断演变的社会对生育治疗的态度，使亚太地区成为最具活力和持续增长潜力的市场之一。

不孕不育的原因

  • 男性不孕
  • 女性不孕症
  • 不明原因的不孕症

免费客製化服务

此报告的订阅者可以从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 简介

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 主要研究资料
    • 二手研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 市场机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 企业之间的竞争

5. 全球生育治疗服务市场（依治疗类型）

  • 辅助生殖技术（ART）
    • 体外受精（IVF）
      • 新鲜非供体
      • 冷冻非捐赠者
      • 新捐款者
      • 冻结捐赠者
    • 卵细胞质内单一精虫显微注射术（ICSI）
    • 配子输卵管植入（GIFT）
    • 受精卵输卵管内移植（ZIFT）
    • 其他辅助生殖技术
  • 人工授精（AI）
    • 子宫内授精（IUI）
    • 子宫颈内授精（ICI）
    • 其他人工授精

6. 全球生育治疗服务市场（依不孕症原因划分）

  • 男性不孕
  • 女性不孕症
  • 不明原因的不孕症

7. 全球生育治疗服务市场（依最终用户）

  • 不孕不育诊所
  • 医院
  • 手术中心
  • 精子库
  • 临床研究所

8. 全球生育治疗服务市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併与收购（M&A）
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章：企业概况

  • CooperSurgical, Inc.
  • Merck KGaA
  • Vitrolife
  • Ferring Pharmaceuticals
  • IVI RMA Global
  • Kindbody
  • Inception Fertility
  • Progyny, Inc.
  • Monash IVF Group
  • Virtus Health
  • Boston IVF
  • Shady Grove Fertility
  • Carrot Fertility
  • Thermo Fisher Scientific Inc.
  • Cook Medical
  • FUJIFILM Irvine Scientific
  • Hamilton Thorne Ltd.
  • Nova IVF Fertility
  • Genea Biomedx
Product Code: SMRC30309

According to Stratistics MRC, the Global Fertility Services Market is accounted for $49.4 billion in 2025 and is expected to reach $85.8 billion by 2032 growing at a CAGR of 8.2% during the forecast period. Fertility services encompass a range of medical treatments, diagnostic procedures, and support solutions designed to assist individuals or couples in achieving pregnancy. These include assisted reproductive technologies (ART) such as in vitro fertilization (IVF), intrauterine insemination (IUI), fertility preservation, hormonal therapies, and diagnostic testing. Market growth is driven by rising infertility rates, delayed childbearing, and increasing awareness of reproductive health, supported by technological advancements and expanding access to specialized fertility clinics and care networks.

Market Dynamics:

Driver:

Rising Infertility Rates

According to the World Health Organization's 2023 report, approximately one in six adults worldwide face infertility challenges, affecting about 17.5% of the adult population. Lifestyle modifications, including obesity, chronic stress, and excessive alcohol consumption, and prevalent medical conditions such as polycystic ovary syndrome (PCOS) significantly contribute to declining fertility rates. Furthermore, the growing trend of delayed parenthood in urban populations has resulted in decreased egg quality among older women, intensifying the demand for advanced fertility interventions and creating substantial market opportunities for service providers globally.

Restraint:

High cost of fertility treatments

Fertility procedures, particularly in vitro fertilization (IVF) and advanced assisted reproductive technologies require considerable financial investment that often extends beyond single treatment cycles. Many patients require multiple attempts to achieve successful pregnancy outcomes, compounding the overall cost burden. Additionally, limited insurance coverage for fertility treatments in various regions forces couples to bear out-of-pocket expenses. This economic constraint particularly affects middle-income families who earn too much to qualify for assistance programs yet not enough to afford comprehensive fertility treatments comfortably.

Opportunity:

Expansion in emerging markets

Countries across Asia-Pacific, Latin America, and developing regions are witnessing rapid expansion of fertility clinics and specialized treatment centers. Government initiatives supporting reproductive healthcare access, coupled with growing awareness about fertility preservation options, create favorable market conditions. Moreover, the rise of medical tourism in emerging markets offers cost-effective fertility solutions to international patients, establishing these regions as global fertility hubs.

Threat:

Cultural and religious opposition

Traditional beliefs regarding fertility treatments, particularly those involving donor gametes or surrogacy arrangements, create resistance among certain populations. Religious doctrines opposing artificial reproductive interventions limit market acceptance and utilization rates in specific communities. Additionally, societal stigma surrounding infertility issues prevents many couples from seeking necessary treatments, reducing overall market demand. Furthermore, varying legal frameworks and ethical considerations across different countries create operational complexities for service providers, potentially limiting expansion strategies.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted fertility services globally, with many clinics temporarily suspending non-essential procedures during lockdowns. However, the market demonstrated remarkable resilience as governments supported the reopening of infertility centers with enhanced safety protocols. Many couples utilized this period for treatment planning, leading to increased demand following service resumption. Additionally, pandemic-induced stress and delayed pregnancies during lockdowns subsequently drove higher fertility service utilization rates, contributing to market recovery and growth acceleration in the post-pandemic period.

The female infertility segment is expected to be the largest during the forecast period

The female infertility segment is expected to account for the largest market share during the forecast period due to various physiological and lifestyle factors affecting women's reproductive health. Rising prevalence of conditions such as polycystic ovary syndrome (PCOS), endometrial tuberculosis, and premature ovarian failure significantly contribute to female infertility rates. Moreover, the increasing trend of delayed childbearing among career-focused women in urban areas results in age-related fertility decline, driving demand for specialized treatments. Advanced diagnostic techniques for female fertility assessment, coupled with innovative treatment options including egg freezing and hormonal therapies, further solidify this segment's leadership position.

The fertility clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fertility clinics segment is predicted to witness the highest growth rate, driven by their specialized focus and comprehensive treatment offerings. These dedicated facilities provide state-of-the-art equipment, specialized expertise, and personalized care protocols specifically designed for reproductive treatments. The segment benefits from the increasing establishment of standalone fertility centers worldwide, particularly in developed regions where advanced technologies such as AI-driven embryo selection and time-lapse imaging are being implemented. Additionally, fertility clinics' ability to offer both standard and complex treatments under one roof, combined with their higher success rates and partnerships with sperm and egg banks, positions them for sustained growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. The region's dominance stems from advanced healthcare infrastructure, high awareness levels about fertility treatments, and comprehensive insurance coverage in many areas. The United States particularly drives regional growth with its presence of leading fertility clinics, technological innovations, and widespread acceptance of assisted reproductive technologies. Additionally, the growing trend of delayed parenthood among North American couples, combined with increasing prevalence of infertility and supportive regulatory frameworks, reinforces the region's market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapid economic development and improving healthcare infrastructure. Countries including China, India, and Southeast Asian nations are witnessing substantial increases in fertility clinic establishments and treatment accessibility. Rising disposable incomes, growing awareness about fertility preservation options, and increasing acceptance of modern reproductive technologies contribute to this remarkable growth trajectory. Furthermore, government initiatives supporting reproductive healthcare, coupled with the region's large population base and evolving social attitudes toward fertility treatments, position Asia Pacific as the most dynamic and promising market for sustained expansion.

Key players in the market

Some of the key players in Fertility Services Market include CooperSurgical, Inc., Merck KGaA, Vitrolife, Ferring Pharmaceuticals, IVI RMA Global, Kindbody, Inception Fertility, Progyny, Inc., Monash IVF Group, Virtus Health, Boston IVF, Shady Grove Fertility, Carrot Fertility, Thermo Fisher Scientific Inc., Cook Medical, FUJIFILM Irvine Scientific, Hamilton Thorne Ltd., Nova IVF Fertility, and Genea Biomedx.

Key Developments:

In February 2024, CooperSurgical has acquired the fertility business from the LifeGlobal(R) Group, a pioneer and global leader within IVF. With this acquisition, we are taking yet another step towards providing our customers with the strongest possible solutions that consist of high-quality products and services, to help specialists improve patient outcomes and increase chances of a healthy pregnancy.

In September 2023, Merck, a leading science and technology company, is launching a comprehensive Fertility Benefit program in October 2023 that will offer employees financial support for fertility treatments. The program will be launched in eight markets: Germany, the United Kingdom, Switzerland, China, India, Taiwan, Brazil, and Mexico. To date, Merck offers similar benefits to employees in the United States, Canada, and Japan. An expansion of the offering to Merck employees in further countries is planned to start next year.

In July 2023, To extend the benefits of genomic testing research for reproductive health labs, Thermo Fisher Scientific launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research. The Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit mark the first research use reproductive health assays available on the Ion Torrent Genexus Integrated Sequencer, delivering complete workflows from sample to result for aneuploidy analysis.

Treatment Types Covered:

  • Assisted Reproductive Technology (ART)
  • Artificial Insemination (AI)

Infertility Causes:

  • Male Infertility
  • Female Infertility
  • Unexplained Infertility

End Users Covered:

  • Fertility Clinics
  • Hospitals
  • Surgical Centers
  • Cryobanks
  • Clinical Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fertility Services Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Assisted Reproductive Technology (ART)
    • 5.2.1 In-Vitro Fertilization (IVF)
      • 5.2.1.1 Fresh Non-Donor
      • 5.2.1.2 Frozen Non-Donor
      • 5.2.1.3 Fresh Donor
      • 5.2.1.4 Frozen Donor
    • 5.2.2 Intracytoplasmic Sperm Injection (ICSI)
    • 5.2.3 Gamete Intrafallopian Transfer (GIFT)
    • 5.2.4 Zygote Intrafallopian Transfer (ZIFT)
    • 5.2.5 Other Assisted Reproductive Technologies
  • 5.3 Artificial Insemination (AI)
    • 5.3.1 Intrauterine Insemination (IUI)
    • 5.3.2 Intracervical Insemination (ICI)
    • 5.3.3 Other Artificial Inseminations

6 Global Fertility Services Market, By Infertility Cause

  • 6.1 Introduction
  • 6.2 Male Infertility
  • 6.3 Female Infertility
  • 6.4 Unexplained Infertility

7 Global Fertility Services Market, By End User

  • 7.1 Introduction
  • 7.2 Fertility Clinics
  • 7.3 Hospitals
  • 7.4 Surgical Centers
  • 7.5 Cryobanks
  • 7.6 Clinical Research Institutes

8 Global Fertility Services Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 CooperSurgical, Inc.
  • 10.2 Merck KGaA
  • 10.3 Vitrolife
  • 10.4 Ferring Pharmaceuticals
  • 10.5 IVI RMA Global
  • 10.6 Kindbody
  • 10.7 Inception Fertility
  • 10.8 Progyny, Inc.
  • 10.9 Monash IVF Group
  • 10.10 Virtus Health
  • 10.11 Boston IVF
  • 10.12 Shady Grove Fertility
  • 10.13 Carrot Fertility
  • 10.14 Thermo Fisher Scientific Inc.
  • 10.15 Cook Medical
  • 10.16 FUJIFILM Irvine Scientific
  • 10.17 Hamilton Thorne Ltd.
  • 10.18 Nova IVF Fertility
  • 10.19 Genea Biomedx

List of Tables

  • Table 1 Global Fertility Services Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Fertility Services Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Fertility Services Market Outlook, By Assisted Reproductive Technology (ART) (2024-2032) ($MN)
  • Table 4 Global Fertility Services Market Outlook, By In-Vitro Fertilization (IVF) (2024-2032) ($MN)
  • Table 5 Global Fertility Services Market Outlook, By Fresh Non-Donor (2024-2032) ($MN)
  • Table 6 Global Fertility Services Market Outlook, By Frozen Non-Donor (2024-2032) ($MN)
  • Table 7 Global Fertility Services Market Outlook, By Fresh Donor (2024-2032) ($MN)
  • Table 8 Global Fertility Services Market Outlook, By Frozen Donor (2024-2032) ($MN)
  • Table 9 Global Fertility Services Market Outlook, By Intracytoplasmic Sperm Injection (ICSI) (2024-2032) ($MN)
  • Table 10 Global Fertility Services Market Outlook, By Gamete Intrafallopian Transfer (GIFT) (2024-2032) ($MN)
  • Table 11 Global Fertility Services Market Outlook, By Zygote Intrafallopian Transfer (ZIFT) (2024-2032) ($MN)
  • Table 12 Global Fertility Services Market Outlook, By Other Assisted Reproductive Technologies (2024-2032) ($MN)
  • Table 13 Global Fertility Services Market Outlook, By Artificial Insemination (AI) (2024-2032) ($MN)
  • Table 14 Global Fertility Services Market Outlook, By Intrauterine Insemination (IUI) (2024-2032) ($MN)
  • Table 15 Global Fertility Services Market Outlook, By Intracervical Insemination (ICI) (2024-2032) ($MN)
  • Table 16 Global Fertility Services Market Outlook, By Other Artificial Inseminations (2024-2032) ($MN)
  • Table 17 Global Fertility Services Market Outlook, By Infertility Cause (2024-2032) ($MN)
  • Table 18 Global Fertility Services Market Outlook, By Male Infertility (2024-2032) ($MN)
  • Table 19 Global Fertility Services Market Outlook, By Female Infertility (2024-2032) ($MN)
  • Table 20 Global Fertility Services Market Outlook, By Unexplained Infertility (2024-2032) ($MN)
  • Table 21 Global Fertility Services Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Fertility Services Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 23 Global Fertility Services Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 24 Global Fertility Services Market Outlook, By Surgical Centers (2024-2032) ($MN)
  • Table 25 Global Fertility Services Market Outlook, By Cryobanks (2024-2032) ($MN)
  • Table 26 Global Fertility Services Market Outlook, By Clinical Research Institutes (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.